

6 References

1. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. *Leukemia*. 2009;23:3-9.
2. Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. *Nat Rev Dis Primers*. 2017;3:17046.
3. Bianchi G, Anderson KC. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. *CA Cancer J Clin*. 2014;64:422-444.
4. Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P. Bone disease in multiple myeloma: pathophysiology and management. *Cancer Growth Metastasis*. 2014;7:33-42.
5. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review 1975-2018, National Cancer Institute, Bethesda, MD, USA, 2021. Updated April 2021. https://seer.cancer.gov/archive/csr/1975_2018/. Accessed December 21, 2022.
6. Gormley N, Fashoyin-Aje L, Locke T, et al. Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. *Blood Cancer Discov*. 2021;2:119-124.
7. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. *BMC Cancer*. 2020;20:1087.
8. Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. *Leukemia*. 2022;36:1371-1376.
9. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia*. 2019;33:2266-2275.
10. Moreau P, Weisel K, De Stefano V, et al. P-264: Updated results from LocoMMotion: a prospective, noninterventional, multinational study of real-life current standards-of-care in heavily pretreated patients with relapsed/refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2022;22:S182-S183.
11. Engelhardt M, Ihorst G, Singh M, et al. Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. *Clin Lymphoma Myeloma Leuk*. 2021;21:e160-e175.
12. Cohen AD, Hari P, Htut M, et al. Patient perceptions regarding ciltacabtagene autoleucel treatment: qualitative evidence from interviews with patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study. *Clin Lymphoma Myeloma Leuk*. 2023;23:68-77.
13. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. *N Engl J Med*. 2019;381:727-738.

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [June 16, 2023]

14. Munshi NC, Anderson LD, Jr., Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. *N Engl J Med*. 2021;384:705-716.
15. Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. *N Engl J Med*. 2022;387:495-505.
16. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. abstract. *J Clin Oncol*. 2023;41 (suppl 16):Abstract 8009.
17. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. *Mayo Clin Proc*. 2016;91:101-119.
18. Epstein J, Walker R. Myeloma and bone disease: "the dangerous tango". *Clin Adv Hematol Oncol*. 2006;4:300-306.
19. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. *Leukemia*. 2008;22:1485-1493.
20. Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. *Am Fam Physician*. 2017;95:373-383.
21. Smith D, Yong K. Multiple myeloma. *BMJ*. 2013;346:f3863.
22. Rodriguez-Otero P, Paiva B, Engelhardt M, Prosper F, San Miguel JF. Is immunotherapy here to stay in multiple myeloma? *Haematologica*. 2017;102:423-432.
23. Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. *J Clin Oncol*. 2004;22:3212-3214.
24. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) version 3.2023. Updated December 8, 2022. <https://www.nccn.org/guidelines/guidelines-detail?category=patients&id=24>.
25. Food and Drug Administration. Lenalidomide (Revlimid). <https://www.fda.gov/drugs/resources-information-approved-drugs/lenalidomide-revlimid>. Accessed April 10, 2023.
26. Food and Drug Administration. Application number: 021430 approval letter (2006).
27. National Cancer Institute. Pomalidomide plus low-dose dexamethasone improves survival for patients with multiple myeloma. <https://www.cancer.gov/types/myeloma/research/pomalidomide-dexamethasone>. Accessed April 10, 2023.
28. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. *Oncologist*. 2003;8:508-513.

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [June 16, 2023]

29. Herndon TM, Deisseroth A, Kaminskas E, et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. *Clin Cancer Res.* 2013;19:4559-4563.
30. Takeda Pharmaceutical Company Limited. U.S. FDA approves Takeda's NINLARO® (ixazomib), the first and only oral proteasome inhibitor to treat multiple myeloma. <https://www.takeda.com/newsroom/newsreleases/2015/u.s.-fda-approves-takedas-ninlaro-ixazomib-the-first-and-only-oral-proteasome-inhibitor-to-treat-multiple-myeloma>. Accessed on 10 April, 2023
31. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. *J Immunol.* 2011;186:1840-1848.
32. Bhatnagar V, Gormley NJ, Luo L, et al. FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy. *Oncologist.* 2017;22:1347-1353.
33. Dhillon S. Isatuximab: first approval. *Drugs.* 2020;80:905-912.
34. van de Donk N. Sequencing multiple myeloma therapies with and after antibody therapies. *Hematology Am Soc Hematol Educ Program.* 2020;2020:248-258.
35. de Arriba de la Fuente F, Montes Gaisan C, de la Rubia Comos J. How to manage patients with lenalidomide-refractory multiple myeloma. *Cancers (Basel).* 2022;15:155.
36. Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. *Lancet.* 2020;396:186-197.
37. Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. *Lancet Oncol.* 2022;23:65-76.
38. Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet.* 2021;397:2361-2371.
39. Moreau P, Dimopoulos MAC, Mikhael J, et al. VP5-2022: updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM). *Ann Oncol.* 2022;33:664-665.
40. Food and Drug Administration. FDA approves new treatment for refractory multiple myeloma. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-refractory-multiple-myeloma>. Accessed April 10, 2023.

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [June 16, 2023]

41. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncol*. 2020;21:207-221.
42. Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. *Cancer*. 2021;127:4198-4212.
43. Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. *Proc Natl Acad Sci U S A*. 2019;116:9543-9551.
44. Zhao WH, Liu J, Wang BY, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. *J Hematol Oncol*. 2018;11:141.
45. Zhao WH, Wang BY, Chen LJ, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). *J Hematol Oncol*. 2022;15:86.
46. Mi JQ, Zhao WH, Chen LJ, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T – at least 5-year follow-up in LEGEND-2. abstract. *J Clin Oncol*. 2023;41 (suppl 16):Abstract 8010.
47. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet*. 2021;398:314-324.
48. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. *J Clin Oncol*. 2023;41:1265-1274.
49. Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. *Front Immunol*. 2018;9:1821.
50. Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. *Immunotherapy*. 2015;7:1187-1199.
51. Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. *Blood*. 2002;100:2175-2186.
52. Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. *Blood*. 2014;123:3128-3138.
53. Bouchkouj N, Kasamon YL, de Claro RA, et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. *Clin Cancer Res*. 2019;25:1702-1708.

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [June 16, 2023]

54. Kymriah USPI. KYMRIA® (tisagenlecleucel) prescribing information. https://www.novartis.com/us-en/sites/novartis_us/files/kymriah.pdf. Accessed May 18, 2023.
55. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. *Annu Rev Med*. 2014;65:333-347.
56. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. *Am J Hematol*. 2019;94:S3-S9.
57. Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. *Trends Immunol*. 2015;36:494-502.
58. Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. *Clin Transl Immunology*. 2019;8:e1049.
59. Blaesche F, Stenger D, Kaeuferle T, et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4(+) and CD8(+) CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19(+) acute lymphoblastic leukemia. *Cancer Immunol Immunother*. 2018;67:1053-1066.
60. Zudaire E, Madduri D, Usmani SZ, et al. Translational analysis from CARTITUDE-1, an ongoing phase 1b/2 study of JNJ-4528 BCMA-targeted CAR-T cell therapy in relapsed and/or refractory multiple myeloma (R/R MM), Indicates preferential expansion of CD8+ T cell central memory cell subset. *Blood*. 2019;134:928-928.
61. Madduri D, Usmani SZ, Jagannath S, et al. Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). *Blood*. 2019;134:577.
62. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. *JAMA Oncol*. 2017;3:28-35.
63. Martin T, Mikhael J, Hajek R, et al. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. *Blood Adv*. 2022;6:4506-4515.
64. Jakubowiak A, Usmani SZ, Berdeja JG, et al. Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 subgroup analysis. *Blood*. 2021;138:3938.
65. Costa LJ, Lin Y, Cornell RF, et al. Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed/refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2022;22:326-335.
66. Mi J-Q, Zhao W, Jing H, et al. Phase 2, open-label study of ciltacabtagene autoleucel, an anti-BCMA CAR-T cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1): 26-month median follow-up. *Blood*. 2022;140:7542-7544.

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [June 16, 2023]

67. Martin T, Lin Y, Agha M, et al. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. *Lancet Haematol*. 2022;9:e897-e905.
68. Legend Biotech USA Inc. U.S. Food and Drug Administration grants breakthrough therapy designation for JNJ-68284528, an investigational BCMA CAR-T cell therapy. https://legendbiotech.com/wp-content/uploads/2022/08/JNJ4528_Breakthrough_Therapy_Designation_Release.pdf. Accessed March 21, 2023.
69. The Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen announces CAR-T therapy ciltacabtagene autoleucel (Cilta-cel) accepted for accelerated assessment in Europe for the treatment of patients with heavily pretreated multiple myeloma. <https://www.businesswire.com/news/home/20210201005446/en/Janssen-Announces-CAR-T-Therapy-Ciltacabtagene-Autoleucel-Cilta-cel-Accepted-for-Accelerated-Assessment-in-Europe-for-the-Treatment-of-Patients-with-Heavily-Pretreated-Multiple-Myeloma>. Accessed March 21, 2023.
70. Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. *J Immunother*. 2009;32:689-702.
71. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med*. 2011;365:725-733.
72. Teoh J, Brown LF. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19(+) hematologic indications. *Cytotherapy*. 2022;24:962-973.
73. Gilead Sciences Inc. TECARTUS (brexucabtagene autoleucel) prescribing information. <https://www.gilead.com/-/media/files/pdfs/medicines/oncology/tecartus/tecartus-pi.pdf>. Accessed April 10, 2023.
74. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR t-cell therapy bb2121 in relapsed or refractory multiple myeloma. *N Engl J Med*. 2019;380:1726-1737.
75. Martin T, Krishnan A, Yong K, et al. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. *EJHaem*. 2022;3:97-108.
76. Weisel K, Martin T, Krishnan A, et al. Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician's choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS clinical trials for the treatment of patients with relapsed or refractory multiple myeloma. *Clin Drug Investig*. 2022;42:29-41.
77. Mateos MV, Weisel K, Martin T, et al. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice [published online ahead of print, 2022 Dec 22]. *Haematologica*. 2022;10.3324/haematol.2022.280482.

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [June 16, 2023]

78. Martin T, Usmani SZ, Schechter JM, et al. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. *Curr Med Res Opin*. 2023;39:81-89.

79. Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. *Blood Cancer J*. 2022;12:47.

80. Dhakal B, Yong K, Harrison S, et al. First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. abstract. *J Clin Oncol*. 2023; Accepted. Abstract 106.

81. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. . *N Engl J Med*. 2023;doi: 10.1056/NEJMoa2303379. Online ahead of print. .

82. The Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen announces unblinding of phase 3 CARTITUDE-4 study of CARVYKTI® (cilta-cel) as primary endpoint met in treatment of patients with relapsed and refractory multiple myeloma. <https://www.jnj.com/janssen-announces-unblinding-of-phase-3-cartitude-4-study-of-carvykti-cilta-cel-as-primary-endpoint-met-in-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma>. Accessed April 7, 2023.

83. Legend Biotech USA Inc. Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel). <https://www.businesswire.com/news/home/20230524005901/en/>. Accessed June 7 2023.

84. The Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma. <https://www.prnewswire.com/news-releases/janssen-submits-supplemental-biologics-license-application-to-us-fda-seeking-approval-of-carvykti-for-the-earlier-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-301844207.html>. Accessed June 7, 2023.

85. Cohen AD, Mateos M-V, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to non-cellular anti-BCMA immunotherapy. *Blood*. 2022;140:4646-4648.

86. Martin T. Thomas Martin, MD, on moving forward with cilta-cel treatment in multiple myeloma. <https://www.cancernetwork.com/view/thomas-martin-md-on-moving-forward-with-cilta-cel-treatment-in-multiple-myeloma>. Accessed April 10, 2023.

87. Legend Biotech USA Inc. Longer-term data from CARTITUDE program continue to show deep and durable responses with ciltacabtagene autoleucel across lines of therapy in patients with multiple myeloma. <https://investors.legendbiotech.com/news-releases/news-release-details/longer-term-data-cartitude-program-continue-show-deep-and>. Accessed April 10, 2023.

88. Legend Biotech USA Inc. CARVYKTI™ (ciltacabtagene autoleucel), BCMA-directed CAR-T therapy, receives U.S. FDA approval for the treatment of adult patients with relapsed or

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [June 16, 2023]

refractory multiple myeloma. <https://investors.legendbiotech.com/news-releases/news-release-details/carvykti-ciltacabtagene-autoleucel-bcma-directed-car-t-therapy>. Accessed April 10, 2023.